throbber
Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 1 of 17 PageID #: 2036
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`MEDA PHARMACEUTICALS INC. and
`CIPLA LTD.,
`
`
`C.A. No. 14-1453-LPS
`
`Plaintiffs,
`
`
`v.
`
`APOTEX INC. and APOTEX CORP.,
`
`
`Defendants.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`AMENDED JOINT CLAIM CONSTRUCTION CHART
`
`On January 20, 2016, the parties submitted a letter to the Court informing it of the likely
`
`addition of a new patent to this case. The parties jointly requested that the Court adjourn the
`
`Markman hearing until after the new patent issued and was added to the case. As a result of this
`
`letter, the Court adjourned the Markman hearing until April 29, 2016 and ordered the parties to
`
`limit any supplemental claim construction briefing “exclusively to new claim terms and claim
`
`construction issues arising from the issuance of” the application that issued as U.S. Patent No.
`
`9,259,428 (“the ’428 patent”). The parties respectfully submit this Amended Joint Claim
`
`Construction Chart to apprise the Court of new claim terms and new claim construction issues
`
`arising from the issuance of the ’428 patent.
`
`As part of their discussions regarding the ’428 patent, the parties have agreed to the
`
`following construction:
`
`Term
`“one or more isotonization agents
`is present in an amount that a
`reduction in the freezing point
`from 0.50° C. to 0.56°C is attained
`in comparison to pure water”
`
`Claims
`12 and 25 of the
`’428 patent
`
`Construction
`“one or more isotonization agents are
`present in amounts that cause a total
`freezing point reduction of 0.50° C. to
`0.56° C. in the nasal spray
`formulation in comparison to
`pharmaceutical-grade water”
`
`{01101931;v1 }
`
`
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 2 of 17 PageID #: 2037
`
`As before, the parties have agreed not to present expert discovery in the briefs, at the
`
`Markman hearing, or in their respective technology tutorials. The parties reserve the right to alter
`
`their constructions based on further discovery and their continuing analysis. Each party's
`
`citations shall not be construed so as to prohibit the parties from addressing the opposing party's
`
`designations.
`
`
`
`PROCTOR HEYMAN ENERIO
`
`/s/ Dominick T. Gattuso
`Dominick T. Gattuso (#3630)
`300 Delaware Avenue, Suite 200
`Wilmington, DE 19801
`(302) 472-7300
`dgattuso@proctorheyman.com
`
`Attorneys for Defendants
`Apotex Inc. and Apotex Corp.
`
`
`
`Of Counsel:
`
`Charles B. Klein
`Ilan Wurman
`WINSTON & STRAWN LLP
`1700 K Street, N.W.
`Washington, DC 20006
`(202) 282-5000
`cklein@winston.com
`iwurman@winston.com
`
`George C. Lombardi
`Samuel S. Park
`35 W. Wacker Drive
`Chicago, Illinois 60601-9703
`(312) 558-5600
`glombardi@winston.com
`spark@winston.com
`
`
`
`
`
`
`
`ASHBY & GEDDES
`
`/s/ John G. Day
`Steven J. Balick (#2114)
`John G. Day (#2403)
`Andrew C. Mayo (#5207)
`500 Delaware Ave., 8th Floor
`P.O. Box 1150
`Wilmington, DE 19899
`(302) 654-1888
`sbalick@ashby-geddes.com
`jday@ashby-geddes.com
`amayo@ashby-geddes.com
`
`Attorneys for Plaintiffs
`Meda Pharmaceuticals Inc. and Cipla Ltd.
`
`Of Counsel:
`
`Dennies Varughese
`Uma Everett
`Rami Bardenstein
`Dallin G. Glenn
`Joshua I. Miller
`Josephine J. Kim
`STERNE, KESSLER, GOLDSTEIN & FOX PLLC
`1100 New York Ave., N.W., Suite 800
`Washington, DC 20005-3934
`(202) 371-2600
`
`Dated: March 25, 2016
`
`{01101931;v1 }
`
`
`2
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 3 of 17 PageID #: 2038
`
`EXHIBIT A
`
`
`
`{01101931;v1 }
`
`
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 4 of 17 PageID #: 2039
`
`Exhibit A
`Disputed Terms and Proposed Constructions1
`
`
`
`
`Term
`
`Term/Phrase
`
`Asserted Patent
`Claim(s)
`
`Plaintiffs’ Proposed Construction
`and Intrinsic Evidence
`
`Defendants’ Proposed Construction
`and Intrinsic Evidence
`
`1
`
`“condition(s)”
`
`’723 patent: 1-4, 7, 8,
`10-18, 20-28
`
`’620 patent: 16, 17,
`24
`
`Proposed Construction
`
`Proposed Construction
`
`“condition(s) resulting in or causing
`allergic reaction(s)”
`
`Intrinsic Evidence
`
`’723 patent
`(MED_DYM_00018010-
`MED_DYM_00018025): abstract,
`1:19-62; 1:66-2:5; 2:16-31; 3:27-32;
`3:38-41; 4:7-32; 4:41-53; 4:61-5:4;
`5:47-6:2; 6:10-28; 7:1-27; 7:53-64;
`8:5-11:47 (Examples 1-14); claims
`1, 4-9, 17, 25.
`
`’723 patent PH:
`
`MED_DYM_11300-
`MED_DYM_00011301 (November
`23, 2011 Examiner-Initiated
`
`Plain and ordinary meaning.
`
`To the extent the Court determines that
`this term requires construction, Apotex
`proposes the following construction:
`“disease(s) or illness(es).”
`
`Intrinsic Evidence
`
`’723 patent: Col. 1:35-62; 2:15-26;
`4:41-54; 5:46-58; 6:46-54; 7:19-64;
`claims 1-4, 7, 8, 10-18, 20-28;
`MED_DYM_00018010-18025
`
`’620 patent: Col. 1:26-33; 2:15-27;
`4:41-54; 5:47-59; 6:46-54; 7:19-64;
`claims 16, 17, 24;
`MED_DYM_00018026-18041
`
`
`1 For all citations, the parties incorporate the corresponding passages in the other patent that are substantially duplicative of the
`specification, figures and abstract citations cited.
`
`{01101931;v1 }
`
`1
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 5 of 17 PageID #: 2040
`
`Interview Summary).
`
`MED_DYM_00014516-
`MED_DYM_00014525 (December
`12, 2011 Preliminary Amendment).
`
`MED_DYM_00017819-
`MED_DYM_00017826 (January 26,
`2012 Notice of Allowance), see
`specifically MED_DYM_00017823,
`MED_DYM_00017825.
`
`’620 patent
`(MED_DYM_00018026-
`MED_DYM_00018041): abstract,
`1:10-60; 2:15-30; 3:25-30; 3:36-39;
`4:7-32; 4:41-53; 4:61-5:4; 5:48-6:3;
`6:11-28; 7:1-27; 7:53-64; 8:4-11:43
`(Examples 1-11 and unnumbered
`Examples); claims 1, 7, 9, 13-17, 19,
`24, 25, 28-30, 47-48.
`
`’620 patent PH:
`
`MED_DYM_00000002-
`MED_DYM_00000043 (Transmittal
`of New Application and
`PCT/GB03/02557).
`
`MED_DYM_00000254-
`MED_00000275 (January 23, 2009
`Office Action), see specifically
`MED_DYM_00000266,
`
`U.S. Patent App. Pub. 2009/0291143,
`pp. 1-4, APOTEX_AZFL 0053674-
`53681
`
`U.S. Patent App. Pub. 2009/0318397,
`pp. 1-4, APOTEX_AZFL 0053682-
`689
`
`U.S. Patent No. 2,837,464, Col. 2, 5;
`APOTEX_AZFL 0053838-848
`
`U.S. Patent No. 3,067,197 Col. 10;
`APOTEX_AZFL 0053849-859
`
`U.S. Patent Application No.
`12/879,515, August 16, 2011
`Declaration of Dr. Sujeet Rajan, pp. 1-
`5; APOTEX_AZFL 0061477-481
`
`U.S. Patent Application No.
`10/518,016 filed as PCT No.
`PCT/GB03/02557 (WO 03/105856)
`Original Application, pp. 1, 5-10, 19-
`23; MED_DYM_0000020-000043
`
`PCT application EP02/02317 (WO
`02/070490 AI) (published 9/12/02)
`pp.1-97,
`MED_DYM_00000143 to 240 at 155
`
`July 23, 2009 Response to Office
`Action, pp. 11-18;
`MED_DYM_0000288-306
`
`{01101931;v1 }
`
`2
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 6 of 17 PageID #: 2041
`
`MED_DYM_00000270.
`
`MED_DYM_00000288-
`MED_DYM_00000306 (July 23,
`2009 Amendments and Response To
`Office Action Dated January 23,
`2009), see specifically
`MED_DYM_00000302-
`MED_DYM_00000304.
`
`MED_DYM_00000577-
`MED_DYM_00000596 (April 28,
`2010 Office Action), see specifically
`MED_DYM_00000582,
`MED_DYM_00000594.
`
`MED_DYM_00000609-
`MED_DYM_00000629 (September
`24, 2010 Amendments and
`Response to Final Office Action
`Dated April 28, 2010), see
`specifically MED_DYM_00000613-
`MED_DYM_000000617,
`MED_DYM_00000622,
`MED_DYM_00000627-
`MED_DYM_00000628.
`
`MED_DYM_00000765-
`MED_DYM_00000780 (February
`16, 2011 Office Action), see
`specifically MED_DYM_00000769,
`MED_DYM_00000773,
`MED_DYM_00000775-
`
`April 28, 2010 Office Action, pp. 1-
`17, MED_DYM_0000578-594
`
`September 24, 2010 Response to
`Office Action, pp. 1-15,
`MED_DYM_0000609-623
`
`August 16, 2011 Amendments and
`Response to Office Action, pp. 1-29,
`MED_DYM_0000793-820
`
`Busse W W et al: “Corticosteroid-
`Sparing Effect of Azelastine in the
`Management of Bronchial Asthma”—
`American Journal of Respiratory and
`Critical Care Medicine, American
`Lung Association, new York, NW,
`vol. 153, No. 1, 1996, pp. 122-127.
`MED_DYM_00000128-133.
`
`Database Medline Online! US
`National Library of Medicine (NLM),
`Bethesda, MD, US: 2000 Portmann D
`et al: Acceptability of local treatment
`of allergic rhinitis with a combination
`of a corticoid (beclomethasone) and an
`antihistaminic (azelastine); vol. 121,
`No. 4, 2000, pp. 273-279, Abstract.
`MED_DYM_0000135
`
`Foreign communication Examination
`Report, EP Application 03738280.1,
`Nov. 10, 2005, pp.1-4, MED-
`
`{01101931;v1 }
`
`3
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 7 of 17 PageID #: 2042
`
`MED_DYM_00000777.
`
`DYM0000431-434
`
`MED_DYM_00000793-
`MED_DYM_00000820 (August 16,
`2011 Amendments and Response to
`Office Action Dated February 16,
`2011), see specifically
`MED_DYM_00000794,
`MED_DYM_00000798-
`MED_DYM_00000801,
`MED_DYM_00000806,
`MED_DYM_00000815-
`MED_DYM_00000818.
`
`MED_DYM_00002559-
`MED_DYM_00002571 (October 3,
`2011 Notice of Allowance), see
`specifically MED_DYM_00002567-
`MED_DYM_00002568-
`MED_DYM_00002570.
`
`MED_DYM_00009006-
`MED_DYM_00009014 (January 30,
`2012 Supplemental Notice of
`Allowability).
`
`MED_DYM_00001454-
`MED_DYM_00001460 (Chopra
`Declaration Submitted with August
`16, 2011 Amendment), see
`specifically MED_DYM_00001454-
`MED_DYM_00001460.
`
`MED_DYM_00001334-
`
`4
`
`Foreign communication from the
`priority application—International
`Preliminary Examination Report,
`PCT/GB03/02557, Aug. 26, 2004, pp.
`1-4, MED-DYM_00000435-440.
`
`Dykewicz, Mark S., et al., “Diagnosis
`and management of rhinitis: complete
`guidelines of the joint task force on
`practice parameters in allergy, asthma
`and immunology,” Annals of Allergy,
`Asthma & Immunology, Nov. (Part II)
`1998, vol. 81, pp. 478-518,
`MED_DYM_00000504-544.
`
`Schmidt, M. W., “The new topical
`steroid ciclesonide is effective in the
`treatment of allergic rhinitis,” Journal
`of Clinical Pharmacology, 1999, vol.
`39, pp. 1062-1069,
`MED_DYM_00000726-733.
`
`First Official Action Translation,
`MED_DYM_00002016-021 at 019
`
`Galant, S., et al., “Clinical Prescribing
`of Allergic Rhinitis Medication in the
`Preschool and Young School-Age
`Child, What are the Options?,”
`BioDrugs2001, vol. 15, No. 7, pp.
`453-463, ADIS International Ltd.
`
`{01101931;v1 }
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 8 of 17 PageID #: 2043
`
`MED_DYM_00001433 (Maus
`Declaration), see specifically
`MED_DYM_00001335-
`MED_DYM_00001340,
`MED_DYM_00001347,
`MED_DYM_00001357,
`MED_DYM_00001368,
`MED_DYM_00001374,
`MED_DYM_00001383,
`MED_DYM_00001403.
`
`MED_DYM_00001434-
`MED_DYM_00001453 (Rajan
`Declaration), see specifically
`MED_DYM_00001435-
`MED_DYM_00001437.
`
`Plaintiffs reserve the right to rely
`upon any intrinsic evidence cited by
`Defendants.
`
`MED_DYM_00002148-158 at 149
`
`Baena-Cagnani, C., “Safety and
`Tolerability of Treatments for Allergic
`Rhinitis in Children,” Drug Safety
`2004, vol. 27, No. 12, pp. 883-898,
`ADIS Data Information BV
`MED_DYM_00002199-214 at 210
`
`Gawchik, et al., “Comparison of
`intranasal triamcinolone acetonide
`with oral loratadine in the treatment of
`seasonal ragweed-induced allergic
`rhinitis,” Am. J. Man. Care, 1997, vol.
`3, No. 7, pp. 1052-1058.
`MED_DYM_00002724-730 at 724
`
`PCT application PCT/GB02i04602
`(WO/2003/033000) (Published
`4/24/03) pp. 1-14
`MED_DYM_00003848-866 at 849-
`850
`
`WO/1997/024365, pp. 6-7,
`MED_DYM_00004062-4082
`
`WO/2003/066656, pp. 9-10,
`MED_DYM_00004210-4220
`
`WO/1997/021724, pp. 1, 2, 5,
`MED_DYM_00004328-4332
`
`WO/2004/013156, pp. 3-6,
`
`{01101931;v1 }
`
`5
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 9 of 17 PageID #: 2044
`
`MED_DYM_00004369-4376
`
`WO/2003/013427, pp. 1-2
`MED_DYM_00004390-4391
`
`WO/2002/076933, pp. 7-8,
`MED_DYM_00004417-4425
`
`WO/1999/025359, pp. 7, 10
`MED_DYM_00004584-4594
`
`WO/2003/042229, pp. 5,
`MED_DYM_00004612-4617
`
`WO/2003/066033, pp. 1, 14,
`MED_DYM_00004671-4685
`
`WO/2008/012338, pp. 1, 14,
`MED_DYM_00004849-4863
`
`Nielsen, et al., “Intranasal
`corticosteroids for allergic rhinitis:
`superior relief?” Drugs, 2001, vol. 61,
`No. 11, pp. 1563-1573,
`MED_DYM_00005344-5354.
`
`Salib Rami Jean, et al., “Safety and
`Tolerability Profiles of Intranasal
`Antihistamines and Intranasal
`Corticosteroids in the Treatment of
`Allergic Rhinitis,” Drug Safety 2003,
`vol. 26, No. 12, pp. 863-893, ADIS
`Data Information BV,
`MED_DYM_00005869-5892
`
`{01101931;v1 }
`
`6
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 10 of 17 PageID #: 2045
`
`WO/2000/066522, pp. 96,
`MED_DYM_00006001-6008
`Case l:14—cv—O1453—LPS Document 95 Filed 03/25/16 Page 10 of 17 Page|D #: 2045
`WO/2002/012266, pp. 7-8,
`MED_DYM_00006198-6206
`
`EP0416951, pp. 2,
`MED_DYM_00006263-6264
`WO/2000/066522, pp. 96,
`MED_DYM_00006001-6008
`WO/2001/078736, pp. 3-4, 12,
`MED_DYM_00006587-6599
`W0/2002/012266, pp. 7-8,
`MED_DYM_00006198-6206
`WO/2000/016814, pp. 1, 9,
`MED_DYM_00006604-6614
`EP0416951, pp. 2,
`MED_DYM_00006263-6264
`GB2140800, pp. 3,
`MED_DYM_00006621-6624
`W0/2001/078736, pp. 3-4, 12,
`MED_DYM_00006587-6599
`WO/2000/048587, pp. 1-7,
`MED_DYM_00007157-7165
`W0/2000/016814, pp. 1, 9,
`MED_DYM_00006604-6614
`WO/2001/078741, pp. 1-7,
`MED_DYM_00007775-7782
`GB2140800, pp. 3,
`MED_DYM_00006621-6624
`WO/2001/078739, pp. 1-7,
`MED_DYM_00007791-
`W0/2000/048587, pp. 1-7,
`7802WO/2001/078745, pp. 3, 13,
`MED_DYM_00007157-7165
`MED_DYM_00008003-8016
`W0/2001/078741, pp. 1-7,
`WO/2001/054664, pp. 1,
`MED_DYM_00007775-7782
`MED_DYM_00008143-8144
`W0/2001/078739, pp. 1-7,
`WO/2000/033892, pp. 1,
`MED_DYM_00007791-
`MED_DYM_00008280-8281
`7802WO/2001/078745, pp. 3, 13,
`MED_DYM_00008003-8016
`
`{01101931;v1 }
`
`7
`
`W0/2001/054664, pp. 1,
`MED_DYM_00008143-8144
`
`W0/2000/033892, pp. 1,
`MED_DYM_00008280-8281
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 11 of 17 PageID #: 2046
`
`WO/2002/066422, pp. 7-9,
`MED_DYM_00008571-8580
`
`WO/2002/100879, pp. 1, 5,
`MED_DYM_00008683-8688
`
`WO/2002/026723, pp. 23-24,
`MED_DYM_00008775-8798
`
`U.S. Patent Application No.
`12/879,515, Original Application, pp.
`1-2, 8, 10-13; MED_DYM_00009277-
`9302
`
`August 16, 2011 Declaration of Dr.
`Joachim Maus, pp. 1-7;
`MED_DYM_00009966-9971
`
`U.S. Patent Application Publication
`No. U.S. 2004/0235807 A1 (published
`11/25/04) MED_DYM_00011174-191
`at 179.
`
`WO/1999/001467, pp.33,
`MED_DYM_00011939-1973
`
`WO/1999/025359, pp. 7,
`MED_DYM_00012676-2684
`
`Defendants reserve the right to rely
`upon any intrinsic evidence cited by
`Plaintiffs
`
`{01101931;v1 }
`
`8
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 12 of 17 PageID #: 2047
`
`2
`
`“administration”
`
`’723 patent: 1-4, 7, 8,
`10-18, 20-28
`
`’620 patent: 1-13, 15-
`18, 21, 22, 24-26, 28,
`29, 31, 33, 35-47
`
`Proposed Construction
`
`Proposed Construction
`
`Plain and ordinary meaning. To the
`extent that the Court requires further
`explanation of the plain and ordinary
`meaning of “administration,”
`Plaintiffs propose that the plain and
`ordinary meaning of
`“administration” is “application.”
`
`Intrinsic Evidence
`
`’723 patent
`(MED_DYM_00018010-
`MED_DYM_00018025): title,
`abstract, 1:43-62; 1:66-2:5; 2:19-3:7;
`3:38-41; 3:54-4:32; 4:41-5:4; 5:14-
`20; 5:30-7:64; 8:4-11:48 (Examples
`1-14); claims 1, 4-6, 12-21, 24-28.
`
`’723 patent PH:
`
`MED_DYM_11300-
`MED_DYM_00011301 (November
`23, 2011 Examiner-Initiated
`Interview Summary).
`
`MED_DYM_00014516-
`MED_DYM_00014525 (December
`12, 2011 Preliminary Amendment).
`
`MED_DYM_00017819-
`MED_DYM_00017826 (January 26,
`
`“to administer simultaneously, either
`in the same or different
`pharmaceutical formulations, or
`separately or sequentially”
`
`Intrinsic Evidence
`
`’723 patent: Col. 1:43-63; 4:41-53, 61-
`67; 5:1-4, 47-67; 6:1-2, 46-54; 7:18-
`27, 35-52; claims 1-4, 7, 8, 10-18, 20-
`28; MED_DYM_00018010-18025
`
`’620 patent: Col. 1:39-53; 4:41-53, 61-
`67; 5:1-4, 48-67; 6:1-3, 46-55; 7:18-
`27, 35-52; claims 1-13, 15-18, 21, 22,
`24-26, 28, 29, 31, 33, 35-47;
`MED_DYM_00018026-18041
`
`U.S. Patent App. Pub. 2009/0318397,
`pp. 1-4, APOTEX_AZFL 0053682-
`689
`
`U.S. Patent App. Pub. 2009/0291143,
`pp. 1-4, APOTEX_AZFL 0053674-
`681
`
`U.S. Patent Application No.
`10/518,016 filed as PCT No.
`PCT/GB03/02557 (WO 03/105856),
`Original Application, pp. 1-2, 5-10,
`19-23, MED_DYM_0000020-43Great
`
`{01101931;v1 }
`
`9
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 13 of 17 PageID #: 2048
`
`2012 Notice of Allowance), see
`specifically MED_DYM_00017823,
`MED_DYM_00017825.
`
`’620 patent
`(MED_DYM_00018026-
`MED_DYM_00018041): title,
`abstract, 1:34-2:6; 2:14-3:6; 3:36-39;
`3:52-4:32; 4:41-5:4; 5:13-19; 5:31-
`7:64; 8:4-11:44 (Examples 1-11 and
`unnumbered Examples); claims 1, 5-
`21, 24-34, 38-44, 47-48.
`
`’620 patent PH:
`
`MED_DYM_00000002-
`MED_DYM_00000043 (Transmittal
`of New Application and
`PCT/GB03/02557), see specifically
`MED_DYM_00000039-
`MED_DYM_00000043.
`
`MED_DYM_00000064-
`MED_DYM_00000076 (December
`14, 2004 Preliminary Amendment),
`see specifically
`MED_DYM_00000070-
`MED_DYM_00000076.
`
`MED_DYM_00000254-
`MED_00000275 (January 23, 2009
`Office Action), see specifically
`MED_DYM_00000255,
`
`Britain Appln. No. 0213739.6, pp. 1-
`10, MED_DYM0000082-93
`
`July 23, 2009 Response to Office
`Action, pp. 11-18;
`MED_DYM_0000288-306
`
`April 28, 2010 Office Action, pp. 1-
`17, MED_DYM_0000578-594
`
`September 24, 2010 Response to
`Office Action, pp. 1-15,
`MED_DYM_0000609-623
`
`August 16, 2011 Amendments and
`Response to Office Action, pp. 1-29,
`MED_DYM_0000793-820
`
`EP 1 519 731 B1, pp. 1-11,
`MED_DYM_00000348-358
`
`EP 2 072 051 A1, pp. 1-8,
`MED_DYM_00000362-369
`
`Australian Patent Application AU
`2003244799 B2 (6/13/03)
`MED_DYM_00002077-099 at 083-
`088
`
`Proposed Claim Amendment to
`Korean Patent Application No. 2004-
`7020819
`MED DYM 00002250-255 at 253-254
`
`PCT application PCT/GB02i04602
`
`{01101931;v1 }
`
`10
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 14 of 17 PageID #: 2049
`
`MED_DYM_00000262-274.
`
`MED_DYM_00000288-
`MED_DYM_00000306 (July 23,
`2009 Amendments and Response To
`Office Action Dated January 23,
`2009), see specifically
`MED_DYM_00000291-
`MED_DYM_00000296,
`MED_DYM_00000305.
`
`MED_DYM_00000455-
`MED_DYM_00000473 (Malhotra
`Declaration Submitted with July 23,
`2009 Amendment), see specifically
`MED_DYM_00000455-
`MED_DYM_00000459.
`
`MED_DYM_00000577-
`MED_DYM_00000596 (April 28,
`2010 Office Action), see specifically
`MED_DYM_00000578-596.
`
`MED_DYM_00000609-
`MED_DYM_00000629 (September
`24, 2010 Amendments and
`Response to Final Office Action
`Dated April 28, 2010),
`MED_DYM_00000609;
`MED_DYM_00000613-
`MED_DYM_00000617,
`MED_DYM_00000629.
`
`MED_DYM_00000654-
`
`11
`
`(WO/2003/033000) (Published
`4/24/03) pp. 1-14
`MED_DYM_00003848-866 at 849-
`853
`
`WO/2003/066656, pp. 14-15, pp.18,
`MED_DYM_00004210-4225
`
`WO/2002/076933, pp. 21,
`MED_DYM_00004417-4438
`
`WO/2003/042229, pp. 9,
`MED_DYM_00004612-4621
`
`WO/2003/066033, pp. 18-19,
`MED_DYM_00004671-4690
`
`WO/2003/066036, pp. 15,
`MED_DYM_00004743-4758
`
`WO/2004/019955, pp. 3,
`MED_DYM_00004830-4833
`
`WO/2000/066522, pp. 96,
`MED_DYM_00006001-6008
`
`WO/2002/012266, pp. 17,
`MED_DYM_00006198-6215
`
`EP0416951, pp. 2-6,
`MED_DYM_00006263-6265
`
`WO/2001/078736, pp. 1, 4,
`MED_DYM_00006587-6591
`
`{01101931;v1 }
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 15 of 17 PageID #: 2050
`
`MED_DYM_00000672 (Malhotra
`Declaration submitted with
`September 24, 2010 Amendment),
`see specifically
`MED_DYM_00000654-
`MED_DYM_00000658.
`
`MED_DYM_00000765-
`MED_DYM_00000780 (February
`16, 2011 Office Action), see
`specifically MED_DYM_00000773,
`MED_DYM_00000775-
`MED_DYM_00000777.
`
`MED_DYM_00000793-
`MED_DYM_00000820 (August 16,
`2011 Amendments and Response to
`Office Action Dated February 16,
`2011), see specifically
`MED_DYM_00000794,
`MED_DYM_00000798-
`MED_DYM_00000801,
`MED_DYM_00000820.
`
`MED_DYM_00002559-
`MED_DYM_00002570 (October 3,
`2012 Notice of Allowance), see
`specifically MED_DYM_00002563-
`MED_DYM_00002564,
`MED_DYM_00002567-
`MED_DYM_00002570.
`
`MED_DYM_00009006-
`MED_DYM_00009014 (January 30,
`
`12
`
`WO/2000/048587, pp. 1-7,
`MED_DYM_00007157-7165
`
`WO/2001/078741, pp. 1-7,
`MED_DYM_00007775-7782
`
`WO/2001/078739, pp. 1-7,
`MED_DYM_00007791-
`7802WO/2001/078745, pp. 1,
`MED_DYM_00008003-8004
`
`WO/2002/100879, pp. 17,
`MED_DYM_00008683-8700
`
`WO/2000/049993, pp. 28,
`MED_DYM_00008861-8890
`
`U.S. Patent Application No.
`12/879,515; Original Application, pp.
`2, 8, 10-13; MED_DYM 00009277-
`9302
`
`U.S. Patent Application Publication
`No. U.S. 2004/0235807 A1 (published
`11/25/04) MED_DYM_00011174-191
`at 186.
`
`WO/2002/085296, pp.17,
`MED_DYM_00011403-1420
`
`WO/1992/014472, pp. 4,
`MED_DYM_00011722-1727
`
`WO/2003/033000, pp. 5,
`
`{01101931;v1 }
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 16 of 17 PageID #: 2051
`
`2012 Supplemental Notice of
`Allowability).
`
`MED_DYM_00001454-
`MED_DYM_00001460 (Chopra
`Declaration Submitted with August
`16, 2011 Amendment), see
`specifically MED_DYM_00001455-
`MED_DYM_00001460.
`
`MED_DYM_00012077-2082
`
`WO/2004/019955, pp. 3, MED DYM
`00012948-2951
`
`Defendants reserve the right to rely
`upon any intrinsic evidence cited by
`Plaintiffs
`
`MED_DYM_00001334-
`MED_DYM_00001433 (Maus
`Declaration), see specifically
`MED_DYM_00001335-
`MED_DYM_00001340,
`MED_DYM_00001342-
`MED_DYM_00001343.
`
`MED_DYM_00001434-
`MED_DYM_00001453 (Rajan
`Declaration), see specifically
`MED_DYM_00001435-
`MED_DYM_00001437.
`
`Apotex_AZFL 0053488-
`Apotex_AZFL 0053496 (U.S. App.
`2006/0025391), see specifically
`Apotex_AZFL 0053495-
`Apotex_AZFL 0053496.
`
`’428 patent: claims 1-30;
`MEDA_APTX03490328-
`MEDA_APTX03490343
`
`{01101931;v1 }
`
`13
`
`

`
`Case 1:14-cv-01453-LPS Document 95 Filed 03/25/16 Page 17 of 17 PageID #: 2052
`
`The teachings in the specification of
`the ’428, ’723 and ’620 patents are
`identical. Therefore, the
`specification of the ’428 patent
`offers no new teachings over those
`included in the ’723 and ’620
`patents.
`
`Plaintiffs reserve the right to rely
`upon any intrinsic evidence cited by
`Defendants.
`
`
`{01101931;v1 }
`
`14

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket